Evidence map›Paper›PMID 38102521›Full record

ArticleJournal of cancer survivorship : research and practice2025

Health-related quality of life among prostate cancer survivors with metastatic disease and non-metastatic disease and men without a cancer history in the USA.

Zhiyuan Zheng, Kewei Sylvia Shi, Arif Kamal, David H Howard, Michal Horný, Thomas B Richards, Donatus U Ekwueme, K Robin Yabroff

Abstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Health-related quality of life among cancer survivors: pre-existing chronic conditions are to be given priority.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhiyuan ZhengAmerican Cancer Society, Atlanta, GA, USA. jason.zheng@cancer.org.
Kewei Sylvia ShiAmerican Cancer Society, Atlanta, GA, USA.
Arif KamalAmerican Cancer Society, Atlanta, GA, USA.
David H HowardEmory University Rollins School of Public Health, Atlanta, GA, USA.
Michal HornýEmory University Rollins School of Public Health, Atlanta, GA, USA.
Thomas B RichardsCenters for Disease Control and Prevention, Atlanta, GA, USA.
Donatus U EkwuemeCenters for Disease Control and Prevention, Atlanta, GA, USA.
K Robin YabroffAmerican Cancer Society, Atlanta, GA, USA.
American Cancer Society · USCenters for Disease Control and Prevention · USEmory University · US

Funding

CDC HHS Special Interest Project 19-009 with Emory UniversityIntramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundFew studies have comprehensively compared health-related quality of life (HRQoL) between metastatic prostate cancer survivors, survivors with non-metastatic disease, and men without a cancer history.

methodsWe used the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) data linkage to identify men aged ≥ 65 years enrolled in Medicare Advantage (MA) plans. Prostate cancer survivors were diagnosed between 1988 and 2017 and completed MHOS surveys between 1998 and 2019. We analyzed data from 752 metastatic prostate cancer survivors (1040 survey records), 19,583 localized or regional prostate cancer survivors (non-metastatic; 30,121 survey records), and 784,305 men aged ≥ 65 years without a cancer history in the same SEER regions (1.15 million survey records). We used clustered linear regressions to compare HRQoL measures at the person-level using the Veterans RAND 12 Item Health Survey (VR-12) T-scores for general health and physical and mental component summaries.

resultsCompared to men without a cancer history, prostate cancer survivors were older, more likely to be married, and had higher socioeconomic status. Compared to men without a cancer history, metastatic prostate cancer survivors reported lower general health (T-score differences [95% confidence interval]: - 6.26, [- 7.14, - 5.38], p < .001), physical health (- 4.33, [- 5.18, - 3.48], p < .001), and mental health (- 2.64, [- 3.40, - 1.88], p < .001) component summaries. Results were similar for other VR-12 T-scores. In contrast, non-metastatic prostate cancer survivors reported similar VR-12 T-scores as men without a cancer history. Further analyses comparing metastatic and non-metastatic prostate cancer survivors support these findings.

conclusionInterventions to improve health-related quality of life for men diagnosed with metastatic prostate cancer merit additional investigation. IMPLICATIONS FOR CANCER SURVIVORS: Interventions to improve health-related quality of life for metastatic prostate cancer survivors merit additional investigation.

Indexed as

Cancer SurvivorsProstatic NeoplasmsQuality of LifeAgedAged, 80 and overHumansMaleNeoplasm MetastasisSEER ProgramUnited StatesHRQoLMetastatic diseaseProstate cancerSEER-MHOS

Identifiers

PMID38102521
PMCPMC11180215
OpenAlexW4389816107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.